Physician profile
Mark A Teruel
NPI 1972558039
$661.52
in general payments reported to CMS, 2019-2025
11 companies · $98.72 in 2025
The $98.72 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $395 · 2021: $33.66 · 2022: $36.91 · 2023: $34.97 · 2024: $61.80 · 2025: $98.72.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $179 · Education: $16.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $178.60 |
| Education | $16.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Covidien LP | $221.06 | 2020 | |
| Bard Peripheral Vascular, INC. | $174.40 | 2020 | |
| Abbott Laboratories | $70.32 | 2025 | Cardiomems |
| Travere Therapeutics, INC. | $54.48 | 2022-2024 | |
| Otsuka America Pharmaceutical, INC. | $28.40 | 2025 | Jynarque |
| Amgen INC. | $24.57 | 2024 | Krystexxa |
| Calliditas Therapeutics US INC. | $20.34 | 2024 | |
| Alnylam Pharmaceuticals INC. | $17.79 | 2021 | |
| Fresenius USA Marketing, INC. | $17.51 | 2022 | |
| Horizon Therapeutics Plc | $16.78 | 2023 | Krystexxa |
| Nxstage Medical, INC. | $15.87 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Teruel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.